By Susanna White, Oval Medical Technologies
The past few years have seen a significant increase in the number of high viscosity (HV) formulations (100 – 1000 cP) being developed. Innovations in the field of biologics, as well as an increased interest in the use of Long Acting Injectables (LAIs), mean that autoinjector developers are constantly being challenged by new formulations with increasingly complex flow behaviours. These new formulations can provide a great number of benefits for patients and health care providers through access to cutting edge therapies and by reducing both dosing frequency and delivered volume. However unless they can be delivered in a patient-orientated manner, these benefits cannot be fully realised. There are a number of steps that autoinjector developers can take to meet the challenges posed by such formulations. This poster will focus on some of the techniques that Oval Medical Technologies has used to develop the ArQ™-Bios high viscosity platform (Figure 1).